Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Substudy 06C of an open-label phase I/II umbrella platform trial of investigational therapy plus pembrolizumab and chemotherapy for first-line advanced unresectable or metastatic gastroesophageal adenocarcinoma
CTR20242894Phase 2Active
- Sponsor
- MSD
- Start
- Sep 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, oxaliplatin, fluorouracil, capecitabine, folinic acid in gastroesophageal junction adenocarcinoma, gastric adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by MSD. Started Sep 2024; status: active.
02
Drugs
03
Conditions
gastroesophageal junction adenocarcinomagastric adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20242894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242894.